185 related articles for article (PubMed ID: 27057636)
41. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
[TBL] [Abstract][Full Text] [Related]
43. Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.
Li W; Liu L; Liu D; Jin S; Yang Y; Tang W; Gong L
Biochem Biophys Res Commun; 2016 Mar; 472(1):156-62. PubMed ID: 26915801
[TBL] [Abstract][Full Text] [Related]
44. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
[TBL] [Abstract][Full Text] [Related]
45. CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas.
Jia N; Dong S; Zhao G; Gao H; Li X; Zhang H
J Cancer Res Ther; 2016; 12(2):892-6. PubMed ID: 27461670
[TBL] [Abstract][Full Text] [Related]
46. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q
Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481
[TBL] [Abstract][Full Text] [Related]
47. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.
Takeda T; Izumi H; Kitada S; Uramoto H; Tasaki T; Zhi L; Guo X; Kawatsu Y; Kimura T; Horie S; Nabeshima A; Noguchi H; Wang KY; Sasaguri Y; Kohno K; Yamada S
Tumour Biol; 2014 Oct; 35(10):10555-69. PubMed ID: 25060178
[TBL] [Abstract][Full Text] [Related]
48. Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma.
Kuraishi Y; Uehara T; Kobayashi Y; Nakajima T; Watanabe T; Shimizu A; Ota H; Tanaka E
Pathol Res Pract; 2019 Nov; 215(11):152623. PubMed ID: 31543221
[TBL] [Abstract][Full Text] [Related]
49. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
50. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma.
Yamamoto S; Tomita Y; Hoshida Y; Nagano H; Dono K; Umeshita K; Sakon M; Ishikawa O; Ohigashi H; Nakamori S; Monden M; Aozasa K
Ann Surg Oncol; 2004 Feb; 11(2):165-72. PubMed ID: 14761919
[TBL] [Abstract][Full Text] [Related]
52. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).
Gong C; Zhang Y; Chen Y; Zhang H; Liu X; Xue H; Ji L; Wang L; Yang L; Zhou G; Wan C
Tumour Biol; 2015 Dec; 36(12):9189-99. PubMed ID: 26088450
[TBL] [Abstract][Full Text] [Related]
53. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
54. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.
Yang JY; Jiang SH; Liu DJ; Yang XM; Huo YM; Li J; Hua R; Zhang ZG; Sun YW
Sci Rep; 2015 May; 5():10575. PubMed ID: 26015068
[TBL] [Abstract][Full Text] [Related]
55. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.
Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):437-444. PubMed ID: 27802195
[TBL] [Abstract][Full Text] [Related]
56. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
Wu Z; Zhou L; Ding G; Cao L
Cancer Biomark; 2017; 18(1):35-39. PubMed ID: 27814273
[TBL] [Abstract][Full Text] [Related]
57. High neuropilin 1 expression was associated with angiogenesis and poor overall survival in resected pancreatic ductal adenocarcinoma.
Ben Q; Zheng J; Fei J; An W; Li P; Li Z; Yuan Y
Pancreas; 2014 Jul; 43(5):744-9. PubMed ID: 24632553
[TBL] [Abstract][Full Text] [Related]
58. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
59. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
